METHOD OF COMBINATION TREATMENT OF NON-SMALL CELL LUNG CANCER STAGE 1B-111 WITH CUSTOMIZATION OF ADJUVANT CHEMOTHERAPY Russian patent published in 2016 - IPC G01N33/48 A61K31/282 A61K31/704 A61K31/4375 A61K31/7068 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for combination treatment of non-small cell lung cancer (NSCLC) IB-stage III. Method involves a neoadjuvant chemotherapy and before tumour biopsy material is sampled, from which the total RNA and gene expression level monoresistance of RRM1, TYMS, ABCC5, ERCC1, TOP1, TOP2a, TUBB3 in tumour tissue are determined. Second stage involves courses of neoadjuvant chemotherapy, at the third stage a combination therapy involves radical pneumonectomy or lobectomy, during which the tumour tissue sample is taken as well as visually intact lung tissue/bronchus, in which determination of monoresistance gene expression levels is repeated, then, in the postoperative period on 15 day adjuvant chemotherapy is given with carboplatin dosed AUC6 in 2-5th day cycle at the level of monoresistance gene expression ERCC1 less than 0.5, in combination with one of the cytostatics, selection of which depends on the level of expression of analysed genes monoresistance.

EFFECT: using the invention enables higher clinical effectiveness of treatment in NSCLC IB-stage III.

1 cl, 1 dwg, 4 ex